Alterola Biotech Inc. logo

Alterola Biotech Inc.

Official communications & shareholder information

Shareholder Update

Dear Shareholder,

Further to our previous update regarding the sale of Phytanix Bio to Protagenic Therapeutics, Inc., the Directors of Alterola Biotech Inc. are pleased to share an important and positive development for our company and its shareholders.

Full Resolution of Legal Dispute & Complete Recovery of Alterola’s Assets

We are delighted to confirm that Alterola Biotech Inc. has fully and successfully resolved its legal dispute with Protagenic Therapeutics, Inc. Following the execution of a Settlement Agreement, the original transaction has been entirely unwound, and Alterola has recovered all of its assets in full. This is a significant milestone for the company, and we believe it positions Alterola well for the next chapter of its development.

On February 17, 2026, Protagenic Therapeutics, Inc. entered into both a Settlement Agreement with Alterola Biotech Inc., EMC2 Capital LLC, and the former stockholders of Phytanix Bio, as well as an Unwind, Termination and Share Exchange Agreement. The unwind completed simultaneously with the execution of that agreement on February 17, 2026, providing a clean and definitive conclusion to this matter.

For full details of the transaction unwind, please refer to the SEC Form 8-K filing made by Protagenic Therapeutics, Inc. on February 24, 2026.

A Strong Asset Base & Active Pursuit of Value for Shareholders

With the successful recovery of all of Alterola’s assets — including its cannabinoid, modified stilbenoid, and voltage-gated potassium channel modulator assets (Kv7.2/7.3 agonists) — the company is now firmly focused on unlocking the value of these assets for shareholders.

The Directors are actively exploring all available avenues to raise the necessary funds to advance and develop these assets, or to otherwise monetise them in the best interests of Alterola Biotech Inc. shareholders. We are committed to moving forward with pace and purpose, and to keeping shareholders informed of progress as it is made.

We look forward to sharing further updates with you in due course.

Sincerely,
The Directors of Alterola Biotech Inc.

View SEC Form 8-K Filing (24 February 2026)

Shareholder Update

Dear Shareholder,

This communication is to update you on the status of the transaction entered into on 15 May 2025, whereby Alterola Biotech Inc. entered into a share exchange agreement with Protagenic Therapeutics Inc.

We formally announced this in an 8-K filing with the SEC on 30 June 2025 and, to avoid unnecessary expenditure, filed a Form 15-15D to announce we were becoming non-reporting—hence this update.

In essence, following a shareholder vote of Protagenic Therapeutics, Inc. (expected by 1 September 2025), Alterola shareholders would be provided the opportunity to swap their pro rata shareholding in Alterola Biotech, Inc. (ABTI shares) for shares in Protagenic Therapeutics, Inc. (PTIX shares), with ratios determined on a pro rata basis.

Protagenic Therapeutics, Inc. made an announcement via an 8-K on 13 August 2025 which raises serious concerns to the Alterola Biotech Inc. directors. Accordingly, the directors of Alterola Biotech Inc. are taking appropriate advice to ensure we take the most appropriate actions to best serve the interests of our shareholders. We will provide further updates, as appropriate, to keep you informed of the situation.

Sincerely,
The Alterola Biotech Inc. Directors

SEC 8-K (30 Jun 2025) Form 15-15D PTIX 8-K (13 Aug 2025)